FDA Approvals, Dividends, New Technologies, and Solid Margins Increase Shareholder Value - Research Report on Abbott, Baxter, CareFusion, Haemonetics, and CR Bard

NEW YORK, August 1, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Investors' Reports announced new research reports highlighting Abbott Laboratories (NYSE: ABT), Baxter International Inc. (NYSE: BAX), CareFusion Corporation (NYSE: CFN), Haemonetics Corp. (NYSE: HAE), and CR Bard Inc. (NYSE: BCR). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Abbott Laboratories Research Report

On July 25, 2013, Abbott Laboratories (Abbott) announced that its FreeStyle Precision pro Blood Glucose and β-Ketone Monitoring System, which is an advanced blood glucose monitoring system designed to address key needs of hospital customers, has received US Food and Drug Administration (FDA) clearance. Heather L. Mason, Senior Vice President, Diabetes Care at Abbott, said, "The FreeStyle Precision Pro system represents a significant step forward as we work to provide tools to improve the way hospitals manage patients' glucose levels, It makes the data available in real time, thanks to the meter's new wireless capabilities. With its individually foil-wrapped test strips, the system is also designed to help reduce test strip cross-contamination in hospital environments." The Full Research Report on Abbott Laboratories - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-07-30/ABT]

--

Baxter International Inc. Research Report

On July 23, 2013, Baxter International Inc. (Baxter) announced that its Board of Directors has approved a quarterly dividend of $0.49 per common share. According to Baxter, the dividend is payable on October 1, 2013 to shareholders of record as on September 6, 2013. Robert J. Hombach, CFO of Baxter, said, "We remain committed to a disciplined capital allocation strategy, balancing re-investment for growth with returning meaningful value to our investors," Baxter also stated that it increased its dividend for shareholders by 9% in May 2013, which came in after a 34% increase in the dividend rate, which the Company implemented in 2012. The Full Research Report on Baxter International Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-07-30/BAX]

--

CareFusion Corporation Research Report

On July 25, 2013, CareFusion Corp. (CareFusion) announced a partnership with Our Lady of the Lake Regional Medical Center (Our Lady of the Lake). According to CareFusion, the partnership aims for addition of new CareFusion's technologies in Our Lady of the Lake hospital. The Company informed that these new technologies will also improve medication safety by simplifying and standardizing the medication management process. CareFusion also stated that CareFusion Pyxis ES platform significantly reduces time for nursing and pharmacy to dispense and administer medications because of simpler, more efficient workflows. Rusty Frantz, Senior Vice President and General Manager of Dispensing Technologies at CareFusion,  said, "We look forward to supporting Our Lady of the Lake with the most robust medication dispensing solution available, the new Pyxis ES platform provides the next-generation of technology to support safe medication dispensing and administration efficiency." The Full Research Report on CareFusion Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-07-30/CFN]

--

Haemonetics Corp. Research Report

On July 29, 2013, Haemonetics Corp. (Haemonetics) announced its Q1 FY 2014 financial results (period ending 29, June, 2013) with net revenue of $219.5 million, up 24.4% YoY. Adjusted non-GAAP net income for the quarter totaled approximately $23.8 million, up 46.3% YoY and adjusted non- GAAP diluted EPS of $0.46, up 48.4% YoY. Brian Concannon, Haemonetics' President and CEO, commented, "This quarter we made excellent progress advancing the manufacturing transformation elements of our Value Creation & Capture (VCC) initiatives. We are encouraged that, at the same time, we were able to drive a 270 basis point improvement in adjusted operating margin, enabling us to deliver profit in line with our expectations and affirm our full year adjusted earnings per share guidance range. This was achieved through productivity and cost management efforts that will later be amplified by the full benefits of the VCC initiatives." For full-year FY 2014, the Company anticipates total revenue growth of 7% to 10% YoY. The Full Research Report on Haemonetics Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-07-30/HAE]

--

CR Bard Inc. Research Report

On July 23, 2013, CR Bard Inc. (CR Bard) announced that its Board of Directors has approved a quarterly dividend of 49.5 cents per common share. The dividend is payable on September 30, 2013 to shareholders of record as on September 9, 2013. The Company also stated that this dividend represents an annualized dividend of $1.98 per share. The Full Research Report on CR Bard Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-07-30/BCR]

----

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

http://InvestorsReports.com

SOURCE Investors' Reports